Pulmatrix, Inc. (PULM)
NASDAQ: PULM · Real-Time Price · USD
6.25
+0.73 (13.22%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Pulmatrix Revenue
In the year 2024, Pulmatrix had annual revenue of $7.81M with 6.96% growth. Pulmatrix had revenue of $3.00K in the quarter ending December 31, 2024, a decrease of -99.86%.
Revenue (ttm)
$7.81M
Revenue Growth
+6.96%
P/S Ratio
2.95
Revenue / Employee
$3,903,000
Employees
2
Market Cap
23.06M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.81M | 508.00K | 6.96% |
Dec 31, 2023 | 7.30M | 1.23M | 20.21% |
Dec 31, 2022 | 6.07M | 902.00K | 17.45% |
Dec 31, 2021 | 5.17M | -7.47M | -59.09% |
Dec 31, 2020 | 12.63M | 4.72M | 59.72% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PULM News
- 4 weeks ago - Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets - PRNewsWire
- 5 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - Accesswire
- 5 months ago - PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM - Business Wire
- 5 months ago - Pulmatrix and Cullgen Announce Proposed Merger - PRNewsWire
- 5 months ago - Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 8 months ago - Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 11 months ago - Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation - PRNewsWire
- 1 year ago - Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - PRNewsWire